tbuckley/cabot-search huggingface dataset:
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
Authors: Peter Ström, Kimmo Kartasalo, Henrik Olsson, Leslie Solorzano, Brett Delahunt, Daniel M Berney, David G Bostwick, Andrew J Evans, David J Grignon, Peter A Humphrey, Kenneth A Iczkowski, James G Kench, Glen Kristiansen, Theodorus H van der Kwast, Katia R M Leite, Jesse K McKenney, Jon Oxley, Chin-Chen Pan, Hemamali Samaratunga, John R Srigley, Hiroyuki Takahashi, Toyonori Tsuzuki, Murali Varma, Ming Zhou, Johan Lindberg, Cecilia Lindskog, Pekka Ruusuvuori, Carolina Wählby, Henrik Grönberg, Mattias Rantalainen, Lars Egevad, Martin Eklund
Journal: The Lancet Oncology (2020)
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Authors: Kimberly H. Allison, M. Elizabeth H. Hammond, Mitchell Dowsett, Shannon E. McKernin, Lisa A. Carey, Patrick L. Fitzgibbons, Daniel F. Hayes, Sunil R. Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter, Charles M. Perou, Meredith M. Regan, David L. Rimm, W. Fraser Symmans, Emina E. Torlakovic, Leticia Varella, Giuseppe Viale, Tracey F. Weisberg, Lisa M. McShane, Antonio C. Wolff
Journal: Journal of Clinical Oncology (2020)

PURPOSE To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if &lt; 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines .
P53 Can Predict Outcome After Taxene-Based Adjuvant Chemotherapy in Patients With Early Breast Cancer
Authors: H. Jung An, H.-J. Lee, G. Gong, K.-P. Kim, J.-H. Ahn, K.H. Jung, J.E. Kim, B.H. Son, S.-H. Ahn, S.-B. Kim
Journal: Annals of Oncology (2012)
Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial
Authors: S. Oudard, J.S. de Bono, M. Özgüroglu, S. Hansen, J. Machiels, I. Kocak, G. Gravis, I. Bodrogi, L. Shen, A.O. Sartor
Journal: Annals of Oncology (2012)
Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Authors: Shipra Das, Beny Shapiro, Emily A. Vucic, Sandra Vogt, Dafna Bar-Sagi
Journal: Cancer Research (2020)

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly stromal and weakly immunogenic tumor microenvironment that promotes tumor evolution and contributes to therapeutic resistance. Here, we demonstrate that PDA tumor cell-derived proinflammatory cytokine IL1β is essential for the establishment of the protumorigenic PDA microenvironment. Tumor cell-derived IL1β promoted the activation and secretory phenotype of quiescent pancreatic stellate cells and established an immunosuppressive milieu mediated by M2 macrophages, myeloid-derived suppressor cells, CD1dhiCD5+ regulatory B cells, and Th17 cells. Loss of tumor cell-derived IL1 signaling in tumor stroma enabled intratumoral infiltration and activation of CD8+ cytotoxic T cells, attenuated growth of pancreatic neoplasia, and conferred survival advantage to PDA-bearing mice. Accordingly, antibody-mediated neutralization of IL1β significantly enhanced the antitumor activity of α-PD-1 and was accompanied by increased tumor infiltration of CD8+ T cells. Tumor cell expression of IL1β in vivo was driven by microbial-dependent activation of toll-like receptor 4 (TLR4) signaling and subsequent engagement of the NLRP3 inflammasome. Collectively, these findings identify a hitherto unappreciated role for tumor cell-derived IL1β in orchestrating an immune-modulatory program that supports pancreatic tumorigenesis. SIGNIFICANCE: These findings identify a new modality for immune evasion in PDA that depends on IL1β production by tumor cells through TLR4-NLRP3 inflammasome activation. Targeting this axis might provide an effective PDA therapeutic strategy.
Incidence and Relevance of Proteinuria in Bevacizumab (BV)-Treated Patients (PTS): Pooled Analysis from Randomized Controlled Trials (RCTS)
Authors: R. Lafayette, B. McCall, N.F. Li, L. Chu, P. Werner, A. Das, R.J. Glassock
Journal: Annals of Oncology (2012)
O-0005 FOLFIRI.3 Alternating with Gemcitabine in Patients with Untreated Metastatic Pancreatic Adenocarcinoma: The Randomized Multicenter Ageo Phase II Trial Firgem
Authors: Isabelle Trouilloud, Anne Claire Dupont-Gossard, Pascal Artru, Thierry Lecomte, Melanie Gauthier, Thomas Aparicio, Anne Thirot-Bidault, David Malka, Celine Lobry, Amani Asnacios, Sophie Lacombe, Francine Fein, Olivier Dubreuil, Aziz Zaanan, Franck Bonnetain, Philippe Rougier, Julien Taieb
Journal: Annals of Oncology (2012)
A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion
Authors: M. Nishio, K. Kiura, K. Nakagawa, T. Seto, A. Inoue, M. Maemondo, T. Hida, M. Harada, H. Yoshioka, T. Tamura
Journal: Annals of Oncology (2012)
Feasibility Report of a Randomized Multicenter Controlled Phase III Trial of Adjuvant UFT/LV Therapy after Resection for Liver Metastasis from Colorectal Carcinoma
Authors: J. Yamamoto, K. Hatsuse, N. Kokudo, M. Oba, T. Takayama, S. Miyagawa, Y. Bandai, K. Hasegawa, A. Saiura, M. Makuuchi
Journal: Annals of Oncology (2012)
Phase I Trials of a C-MET Inhibitor ARQ 197 in Combination with an EGFR Inhibitor Erlotinib in Advanced/Metastatic Non-Small Cell Lung Carcinoma (ARQ 197-003/005 Trial)
Authors: Y. Fujisaka, N. Yamamoto, T. Hirashima, K. Takeda, K. Sugio, M. Satouchi, K. Nakagawa
Journal: Annals of Oncology (2012)
Evolving concepts in how viruses impact asthma: A Work Group Report of the Microbes in Allergy Committee of the American Academy of Allergy, Asthma &amp; Immunology
Authors: Matthew C. Altman, Avraham Beigelman, Christina Ciaccio, James E. Gern, Peter W. Heymann, Daniel J. Jackson, Joshua L. Kennedy, Kirsten Kloepfer, Robert F. Lemanske, Laurie M. McWilliams, Lyndsey Muehling, Christy Nance, R. Stokes Peebles
Journal: Journal of Allergy and Clinical Immunology (2020)
CQC review raises “serious concerns” over private provider running 113 mental health facilities
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Staff working at mental health and adult social care services run by private provider Cygnet Health Care told the Care Quality Commission (CQC) that managers had attempted to actively deceive the regulator by “hiding incidents and low staff numbers . . . and concerns regarding the inexperience of staff and lack of training.”

The concerns were shared as part of the CQC’s review of the provider, which took place between 2 July and 2 August 2019. The regulator said that 22 locations had a current breach of regulation (as of April 2019) and in the 12 months up to April 2019 it had had 37 concerns from whistleblowers or staff.

The inspections of Cygnet’s services followed an undercover investigation by BBC Panorama which showed adults with learning disabilities and autism being abused by staff at Whorlton Hall, a specialist hospital in the north east of England.

Nine of Cygnet Health Care’s services have been rated as …
The Impact of Anemia in Advanced Solid Tumors Treated with Sorafenib (SO) and Sunitinib (SU): A Pooled Analysis of 6 Trials
Authors: S. Barni, K.F. Borgonovo, M. Ghilardi, M. Cabiddu, F. Maspero, M. Cremonesi, F. Petrelli
Journal: Annals of Oncology (2012)
G-CSF as Secondary Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Solid Tumors: Results of a Prospective, Observational Study
Authors: G. Freyer, N. Jovenin, G. Yazbek, C.B. Villanueva, A. Hussain, A. Bethune, M. Rotarski, H. Simon, V. Boulanger, M. Hummerlsberger
Journal: Annals of Oncology (2012)
A Phase I Dose Escalation Study Investigating Dovitinib and Everolmus in Combination in Metastatic Clear Cell Renal Cancer Patients who have Previously Failed VEGF Targeted Therapy
Authors: T.B. Powles, R.J. Jones, S. Crabb, S. Sarker, E. Boleti, J. Shamash, N. Sarwar, S. Chowdhury
Journal: Annals of Oncology (2012)
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Authors: Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, Ndiya Ogba
Journal: Journal of the National Comprehensive Cancer Network (2020)

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.
P-0034 An Exacerbated Pro-Inflammatory State may Increase the Risk of H. Pylori-Associated Gastric Cancer Development
Authors: Maryam Esmaily, Yeganeh Talebkhan, Afshin Abdirad, Nazanin Mohajerani, Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Ali Mohagheghi, Zahra Mostakhdemin Hosseini, Marjan Mohammadi
Journal: Annals of Oncology (2012)
Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma: the Latin American Experience
Authors: C. Flores-Balcázar, A. Alvarado-Zermeño, M. Blake-Cerda, A. Mota-García, A. Poitevin-Chacón, S. Rosales-Pérez, G. Trejo-Duran
Journal: Annals of Oncology (2012)
Are we ready for targeted therapy combinations in HCC?
Authors: Einat Cinnamon, Eli Pikarsky
Journal: Gut (2020)

Treatment options for advanced hepatocellular carcinoma (HCC) are limited. Although some multikinase inhibitors such as sorafenib show some benefit, this does not significantly alter the course of disease for most patients. Currently, several multikinase inhibitors were shown to work in first-line or second-line treatments, but the overall benefit is quite small. Thus, we urgently need to find ways to increase response rates and perhaps more important, to be able to sustain responses for longer periods.1 Chemotherapy combinations changed the history of cancer therapy when first introduced in childhood malignancies and such combinations remain the main treatment option for many cancer patients. Some kinase inhibitors were also shown to work better in combination—for example, the combination of B-RAF and MEK inhibitors in advanced melanoma showed significantly improved rates of progression-free and overall survival versus B-RAF inhibition alone.2 The choice of the combination in this case was made based on preclinical data suggesting that MEK activation is a major determinant of progression in vemurafenib (a B-RAF-inhibitor) treated melanomas. In the absence of clear cut mechanisms of acquired resistance to sorafenib (which is a multikinase inhibitor), how can we find drug combinations which will increase its efficacy?

One way to search for therapeutic targets is the loss of function …
Serum Plasma Leptin Levels and Life Expectancy in Cancer Patients with Terminal Illness
Authors: C. Spoto, M. Iuliani, A. Zoccoli, F. Pantano, F.M. Guida, S. Intagliata, V. Limetti, B. Vincenzi, G. Tonini, D. Santini
Journal: Annals of Oncology (2012)
New Option for Sickle Cell Disease
Authors: Rebecca Voelker
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retrospective Study of Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Neurocognitive Analysis
Authors: Y. Nakahara, Y. Hosomi, M. Akahane, Y. Ookuma, Y. Takagi, M. Iguchi, T. Okamura, M. Shibuya, K. Karasawa
Journal: Annals of Oncology (2012)
シスゴルジマトリックスタンパク質GOLGA2/GM130は,抗癌遺伝子治療の新たな標的となる
Authors: Chang Seung-Hee, Hong Seong-Ho, Jiang Hu-Lin, Minai-Tehrani Arash, YU Kyeong-Nam, Lee Jae-Ho, Kim Ji-Eun, Shin Ji-Young, Kang Bitna, Park Sungjin, Han Kiwon, Chae Chanhee, Cho Myung-Haing
Journal: Molecular Therapy (2012)
Clinicians prescribe antibiotics for childhood respiratory tract infection based on assessment, rather than parental expectation
Authors: Rob Cook, Peter Davidson, Alicia White
Journal: BMJ (2020)

The studyCabral C, Horwood J, Symonds J, et al. Understanding the influence of parent-clinician communication on antibiotic prescribing for children with respiratory tract infections in primary care: a qualitative observational study using a conversation analysis approach. BMC Fam Pract 2019;20:102.This project was funded by the NIHR School for Primary Care Research Programme (project number SPCR204).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000829/gps-assessment-not-parental-expectation-drives-antibiotic-prescribing.
Screening and treatment of tuberculosis among pregnant women in Stockholm, Sweden, 2016–2017
Authors: Gabrielle Fröberg, Lena Jansson, Katherine Nyberg, Birgitta Obasi, Katarina Westling, Ingela Berggren, Judith Bruchfeld
Journal: European Respiratory Journal (2020)

Swedish National tuberculosis (TB) guidelines recommend screening of active and latent TB (LTBI) among pregnant women (PW) from high-endemic countries or with previous exposure to possibly improve early detection and treatment. We evaluated cascade of care of a newly introduced TB screening programme of pregnant women in Stockholm county in 2016–2017. The algorithm included clinical data and Quantiferon (QFT) at the Maternal Health Care clinics and referral for specialist care upon positive test or TB symptoms. About 29 000 HIV-negative pregnant women were registered yearly, of whom 11% originated from high-endemic countries. In 2016, 72% of these were screened with QFT, of which 22% were QFT positive and 85% were referred for specialist care. In 2017, corresponding figures were 64%, 19% and 96%, respectively. The LTBI treatment rate among all QFT-positive pregnant women increased from 24% to 37% over time. Treatment completion with mainly rifampicin post-partum was 94%. Of the 69 registered HIV-positive pregnant women, 78% originated from high-endemic countries. Of these, 72% where screened with QFT and 15% were positive, but none was treated for LTBI. 9 HIV-negative active pulmonary TB cases were detected (incidence: 215/100 000). None had been screened for TB prior to pregnancy and only one had sought care due to symptoms. Systematic TB screening of pregnant women in Stockholm was feasible with a high yield of unknown LTBI and mostly asymptomatic active TB. Optimised routines improved referrals to specialist care. Treatment completion of LTBI was very high. Our findings justify TB screening of this risk group for early detection and treatment.
Incidence of Hepatitis B and C Infections in Early Breast Cancer Patients and Impact on Systemic Treatments
Authors: A. Levaggi, G. Iacono, F. Poggio, C. Bighin, S. Giraudi, A. D'Alonzo, M. Lambertini, A. De Maria, P. Pronzato, L. Del Mastro
Journal: Annals of Oncology (2012)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Authors: Anthony R. Cillo, Cornelius H.L. Kürten, Tracy Tabib, Zengbiao Qi, Sayali Onkar, Ting Wang, Angen Liu, Umamaheswar Duvvuri, Seungwon Kim, Ryan J. Soose, Steffi Oesterreich, Wei Chen, Robert Lafyatis, Tullia C. Bruno, Robert L. Ferris, Dario A.A. Vignali
Journal: Immunity (2020)
Prognostic Factors after Conservative Treatment of a Large Series of "Stage I" Serous Borderline Ovarian Tumors
Authors: P. Morice, A. Kane, E. Muller, R. Fauvet, S. Gouy, P. Pautier, C. Lhomme, E. Darai, P. Duvillard, C. Uzan
Journal: Annals of Oncology (2012)
Autologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
Authors: Vladimir Moiseyenko, Irina Alexandrovma Baldueva, Alexey Viktorovich Novik, Tatyana Leonidovna Nehaeva, Anna Borisovna Danilova, Alexey Olegovich Danilov, Tatyana Petrova, Svetlana Protsenko, Tatyana Michailichenko, Anna Igorevna Semenova, Gulfiya Midhatovna Teletaeva
Journal: Journal of Clinical Oncology (2012)

e13059 Background: Low immunogenicity of tumor-associated antigens, cellular and humoral immunosuppressive factors compromise adequate antitumor immune response development. We hypothesized that ADTV, PP and Cy can overcome these immune escape mechanisms by enhancing antigen presentation, suppressing T-regs and removal of various immunosuppressive substances, respectively (Nand S, 1997; Salem M, 2010). Methods: Ten pts (median age 47.3 (24-74)) with stage IV morphologically verified malignant melanoma were included in the study in 2010. All pts signed inform consent form, previously received systemic therapy and have no brain metastases. Pts received 3 procedures of middle-volume PP (removal of 10 ml/kg plasma) on days 1,3,5 of the first 4 cycles, Cy 300 mg IM on day 5 after PP, DCV in 4 intradermal injection of 5-20*10 6 mature DC on day 8 of 14-day cycle. Pts with no evidence of disease progression after 4 cycles received Cy and DCV without PP once in a month for 1 year and once in 3 month thereafter until disease progression. Primary endpoint was Progression Free Survival (PFS). Secondary endpoints were toxicity (per CTCAE), efficacy (per irRECIST) and immune response using ELISpot and whole cell Elisa tests. Median of patient’s observation was 231 days. Results: Ten pts received 73 (2-21) cycles of therapy. No gr. 4 AE or SAE occurred. One patient (1.4% of cycles) developed gr. 3 fever. Main gr. 1-2 toxicities were fever (34.2%), flu-like syndrome (17,8%) and PP-related reactions, such as citrate intoxication, nausea or hypotension (16,4%). One pt achieved PR (10%, 95% CI 0 - 35%) lasting 956+ days. Four pts (40%, 95% CI 13-70%) had SD for 168, 262, 417 and 454 days (3/4-stage M1c). Median PFS was 168 (95% CI 10-325) days. IFN-γ production increased in all patients irrespective of tumor response (p=0.017). All patients with clinical benefit showed increased production of tumor-specific IgG in whole cell ELYSA. Relative risk of disease progression was 6.0 (95% CI 1.003-35.9, p=0.023) in the absence of tumor-specific IgG production. Conclusions: ADCV with PP and C is well tolerated and shows significant immunological and clinical response in pretreated stage IV pts.
Can the Help Match the Hype? KRASG12C-Specific Inhibitors and Beyond
Authors: Samuel J. Klempner, Aaron N. Hata
Journal: Cancer Discovery (2020)

Abstract Summary: Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRASG12C-driven cancers. See related article by Hallin et al., p. 54.
Exteriorisation of Mannoses on Human Erythrocyte Membrane Skeleton Provides 'Eat Me' Signals for Oxidatively Damaged Cells to be Cleared By Macrophages: A Pathway Mediating Hemolysis in Sickle Cell Disease
Authors: Mark A Vickers, Robert N Barker, Huan Cao, Heather J Wassall, Megan A Forrester, Lindsay S Hall, Michael Moss, Sadie Henderson, Gabriela Konieczny, Minter Beverly, Jenna Shepherd, Stuart M Haslam, David C Rees, Heather M Wilson, Dimitrios Tampakis, Maria-Louise Williams
Journal: Blood (2017)